Chardan Capital Boosts Krystal Biotech (NASDAQ:KRYS) Price Target to $208.00

Krystal Biotech (NASDAQ:KRYS) had its price objective upped by Chardan Capital from $153.00 to $208.00 in a research note released on Monday, Benzinga reports. The firm currently has a buy rating on the stock. Chardan Capital also issued estimates for Krystal Biotech’s FY2025 earnings at $8.69 EPS.

A number of other research analysts also recently commented on KRYS. Stifel Nicolaus reiterated a buy rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. HC Wainwright restated a buy rating and set a $200.00 price target on shares of Krystal Biotech in a report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $185.63.

Krystal Biotech Price Performance

KRYS stock opened at $180.37 on Monday. Krystal Biotech has a 1-year low of $93.95 and a 1-year high of $219.34. The company has a market capitalization of $5.15 billion, a price-to-earnings ratio of 96.45 and a beta of 0.84. The business has a 50 day simple moving average of $186.25 and a two-hundred day simple moving average of $164.61.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the previous year, the company earned ($1.25) earnings per share. The company’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. Sell-side analysts anticipate that Krystal Biotech will post 2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently made changes to their positions in KRYS. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech during the second quarter valued at about $28,000. GAMMA Investing LLC boosted its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Key Financial Inc bought a new stake in Krystal Biotech during the second quarter valued at about $28,000. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Krystal Biotech during the second quarter valued at about $71,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).